Vistagen completes Pherin acquisition, reports Q3 net loss $9.8M; PH94B Phase 3 adjusted

Vistagen Therapeutics, Inc.

Acquired Pherin Pharmaceuticals; eliminated all future royalty obligations on PH94B and PH10; added three new pherine candidates.
PH94B Phase 3 plan: PALISADE-1 had unexpected results; preparing FDA meeting; considering multiple-administration LSAS study.
PH10 received FDA Fast Track designation for major depressive disorder; Phase 1 trial underway; Phase 2A AjDA topline results expected Q1 2023.
Q3 net loss $9.8M vs $10.7M YoY; R&D decreased $0.9M to $6.9M; cash $25.0M at Dec 31, 2022.
Shares outstanding 219.3M, including ~12.4M shares issued for Pherin acquisition.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vistagen Therapeutics, Inc. reported financial results for fiscal year 2023 third quarter ended December 31, 2022.

Period: fiscal year 2023 third quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 third quarter ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001851734-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.